Da Hee Han

Most Recent Articles by Da Hee Han

Keytruda Gains Merkel Cell Carcinoma Indication

Keytruda Gains Merkel Cell Carcinoma Indication

By

The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus

Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus

By

Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.

Guselkumab Compared With Secukinumab in Head-to-Head Plaque Psoriasis Trial

Guselkumab Compared With Secukinumab in Head-to-Head Plaque Psoriasis Trial

By

In the ECLIPSE study (N=1048), patients were randomized to receive guselkumab 100mg at weeks 0, 4, and 12 followed by every 8-week dosing or secukinumab 300mg at weeks 0, 1, 2 3, 4 followed by every 4-week dosing.

New Topical Steroid Option for Plaque Psoriasis Soon to Be Available

New Topical Steroid Option for Plaque Psoriasis Soon to Be Available

By

The approval was supported by data from 2 prospective, multicenter, randomized, double-blind clinical trials.

Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis

Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis

By

Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.

More Articles by Da Hee Han

Sign up for Newsletters